Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition - sprookjes - yvandenbroek - TriplyDB

Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition

Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition

http://www.wikidata.org/entity/Q41858907

about

Peri-operative anaesthetic myocardial preconditioning and protection - cellular mechanisms and clinical relevance in cardiac anaesthesia Modulation of caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure in rabbits.Metabolic and Functional Evaluation of the Heart and Lungs in Pulmonary Hypertension by Gated 2-[18F]-Fluoro-2-deoxy-D-glucose Positron Emission Tomography Pulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy.Sevoflurane postconditioning protects rat hearts against ischemia-reperfusion injury via the activation of PI3K/AKT/mTOR signaling The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.Sevoflurane ameliorates intestinal ischemia-reperfusion-induced lung injury by inhibiting the synergistic action between mast cell activation and oxidative stress.Sevoflurane Preconditioning Reduces Intestinal Ischemia-Reperfusion Injury: Role of Protein Kinase C and Mitochondrial ATP-Sensitive Potassium Channel.Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension.Sevoflurane preconditioning in on-pump coronary artery bypass grafting: a meta-analysis of randomized controlled trials.Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.TIR/BB-loop mimetic AS-1 attenuates cardiac ischemia/reperfusion injury via a caveolae and caveolin-3-dependent mechanism.Potential Roles of Serum Caveolin-3 Levels in Patients with Atrial Fibrillation.Canonical and new generation anticancer drugs also target energy metabolism.The role of nuclear imaging in pulmonary hypertension.Early detection of pulmonary arterial hypertension.Caveolae: molecular insights and therapeutic targets for stroke.Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.One-year outcome of the sevoflurane in acute myocardial infarction randomized trial.Caveolin-3 plays a critical role in autophagy after ischemia-reperfusion.Caveolin-1/-3: therapeutic targets for myocardial ischemia/reperfusion injury.Inhibition of PKCβ2 overexpression ameliorates myocardial ischaemia/reperfusion injury in diabetic rats via restoring caveolin-3/Akt signaling.Epidemiology and treatment of pulmonary arterial hypertension.Circulating microRNAs indicate cardioprotection by sevoflurane inhalation in patients undergoing off-pump coronary artery bypass surgery.Molecular imaging of the pulmonary circulation in health and disease.Effects of Sevoflurane and Propofol on Organ Blood Flow in Left Ventricular Assist Devices in Pigs.Sevoflurane preconditioning ameliorates traumatic spinal cord injury through caveolin-3-dependent cyclooxygenase-2 inhibition.The allosteric glycogen synthase kinase-3 inhibitor NP12 limits myocardial remodeling and promotes angiogenesis in an acute myocardial infarction model.Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.Upregulation of vascular endothelial growth factor receptor-1 contributes to sevoflurane preconditioning-mediated cardioprotection.

P2860

Q28085567-513CB947-E9E5-4DB1-B0B7-B60EB11E0D0B Q33675082-3452BA5B-1531-43EB-960E-280903D48E01 Q33788499-88AFFCBF-636A-4D29-9368-7A5DFA83F01F Q33956819-E5652888-78C1-4DE5-81C5-478D379866D4 Q34149206-1F94B426-909E-4202-A689-AC24E4B8C1C7 Q34628699-4621822A-BBF8-4AB8-B7DF-D017DD09F417 Q34924892-72137F26-47F7-43B4-AD48-C67D8DF89003 Q35628595-13AC0E16-D976-43AC-82B5-51900726B289 Q35822771-500AFDA3-1746-4B9A-8545-EEF0BFBD73C2 Q35941642-06B7660D-A62E-4383-A609-A8778E5762D3 Q36105332-39BB1B12-D73E-4CE8-8020-000A6E13D9FD Q36752368-685F5B71-918C-40F8-A45C-CE816B54EEC0 Q37698757-AEAEC748-299F-45E5-9C0D-5C708EDF0250 Q37735999-0806932B-B4F7-4C3B-B019-E0B11BBB52CF Q38208982-2617AB08-5550-4E52-91DF-C9688B66B711 Q38243749-AD7A108F-8C91-4315-BEBC-7B98427ABD14 Q38271027-BF798B60-80D9-469A-AE52-EA57B89FD691 Q38339343-262D366C-06F0-48CC-A9A2-E06EA605C09A Q38403596-65C22DEC-2109-49E6-BCA8-A32920626B49 Q38405526-B78E68DE-9065-41D2-9F01-0F0C1265303B Q38739373-322FA110-DD8E-4C9E-9E6E-3FFCF071AA5A Q38855645-127E6413-6EC5-4FB3-8CA3-BC12E9B9EB43 Q38890008-2128517D-32D3-4149-985A-F458FBC0FC45 Q39359218-59030886-F4D3-46FC-AA4B-D68ADFE8CD55 Q41967015-108F705E-50EF-41B7-BD13-BA66ED5C649E Q42961033-BC44ED3E-E7F5-4B83-875F-7A02AF5490B8 Q43184356-85CDA56F-1A10-4FA3-B39A-3803DF011C34 Q47138142-AF401E85-1784-4EB6-88BC-E3961F041DF9 Q47598692-9F98ECC2-BC7D-47E3-9EB4-BB7E49EC0D41 Q49471057-F328D69A-9321-456C-B619-E6BF8348EF8D Q54968948-31F68CB9-1218-430C-91BF-C1869BEC59F0

P2860

Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition

http://www.wikidata.org/entity/Q41858907

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Sevoflurane preconditioning at ...... nt cyclooxygenase-2 inhibition

@en

type

label

Sevoflurane preconditioning at ...... nt cyclooxygenase-2 inhibition

@en

prefLabel

Sevoflurane preconditioning at ...... nt cyclooxygenase-2 inhibition

@en

P1433

Q41858907-A89D1BBE-1038-4A92-A564-4EC79712E2F5

P1476

Q41858907-30270029-AFDD-4E9F-B5D1-767A5EDA3E17

P2093

Q41858907-182A78A9-4AC2-4206-AA44-21247B76FCA4

Q41858907-1C22262E-3C61-4A69-8AEA-A73B8BC1E90B

Q41858907-364DA50D-6C04-4391-A897-454072EBEF61

Q41858907-4BFB3FF9-E911-44A9-BAB7-2BDF271E2303

Q41858907-5B09AA0E-AB0E-4CB6-B853-8FB07283F22D

Q41858907-72AB390D-186C-451C-9957-D35DEA70CD34

Q41858907-9661E8FD-D4FC-49AA-894E-EB95FFE72A88

Q41858907-BAB9D75C-D280-4A66-B3A1-760A85077690

Q41858907-C3CF60E8-25E0-4E6C-9731-A56256C3B5B5

Q41858907-D37AC801-970D-40EB-8505-5FA5324ADB08

P2860

Q41858907-0085D13F-2081-431F-BDD7-A2BC7B60C0AC

Q41858907-0A6768DD-903D-4A02-98B4-AC7E66D148AE

Q41858907-1005F22C-6BF1-41E9-BD29-2728C3DDD39B

Q41858907-103FEDC7-B2A3-4705-B56D-08AD2E21A607

Q41858907-1FD16E1B-2AD9-4021-AF23-7FAA7672887D

Q41858907-24D12754-5B51-449F-9106-E24E4D7EED37

Q41858907-2B147981-1763-4DB6-A2DF-830F4D90150A

Q41858907-3A092911-0379-4B19-A4D0-AE4705B23916

Q41858907-43B93BE8-5295-498C-9509-59034BE0BA0F

Q41858907-49A6278B-441B-496E-9F5A-66D309F63A43

P304

Q41858907-B45071DE-B6A2-4E6F-94E6-AD1CF77AF041

P31

Q41858907-B6A9CD36-8AA4-426A-BCB4-9CF7D4B6B8C0

P356

Q41858907-AD0819E9-E8C1-430E-851E-B1BC739B7667

P407

Q41858907-6478AFB1-196B-412E-8A63-FE861C0F6C83

P433

Q41858907-B941BD35-9832-4FD3-9F52-6492D892A3B2

P478

Q41858907-808216FD-5017-4068-8797-3F9E05322F6B

P577

Q41858907-609FAA47-EB0E-4FDD-8A7C-1E990C5F85CF

P698

Q41858907-5BDF3EA3-CB76-4203-9F1F-97AD3964BFCA

P921

Q41858907-D9576B67-1D39-406F-86A7-A9132957FA53

P932

Q41858907-EB3CE2C1-7B54-407F-B842-13521A7C43B0

P356

CIRCULATIONAHA.112.000045

P1433

P1476

Sevoflurane preconditioning at ...... nt cyclooxygenase-2 inhibition

@en

P2093

Baojiang Liu

http://www.w3.org/2001/XMLSchema#string

Erhe Gao

http://www.w3.org/2001/XMLSchema#string

Feng Wang

http://www.w3.org/2001/XMLSchema#string

Jianli Zhao

http://www.w3.org/2001/XMLSchema#string

Lili Wang

http://www.w3.org/2001/XMLSchema#string

Liyuan Jiao

http://www.w3.org/2001/XMLSchema#string

Walter J Koch

http://www.w3.org/2001/XMLSchema#string

Wayne Bond Lau

http://www.w3.org/2001/XMLSchema#string

Xin-Liang Ma

http://www.w3.org/2001/XMLSchema#string

Yajing Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac-specific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning

Caveolin-3 expression and caveolae are required for isoflurane-induced cardiac protection from hypoxia and ischemia/reperfusion injury

Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.

Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation.

Role of caveolin-3 and glucose transporter-4 in isoflurane-induced delayed cardiac protection.

A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse.

Essential role of caveolin-3 in adiponectin signalsome formation and adiponectin cardioprotection.

AMP-activated protein kinase deficiency enhances myocardial ischemia/reperfusion injury but has minimal effect on the antioxidant/antinitrative protection of adiponectin.

Cardioprotective effect of adiponectin is partially mediated by its AMPK-independent antinitrative action.

Differences in production of reactive oxygen species and mitochondrial uncoupling as events in the preconditioning signaling cascade between desflurane and sevoflurane.

P304

S121-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.112.000045

http://www.w3.org/2001/XMLSchema#string

P407

P433

11 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24030395

http://www.w3.org/2001/XMLSchema#string

P921

reperfusion injury

P932

3884906

http://www.w3.org/2001/XMLSchema#string